DURAN Group launches anniversary campaign to celebrate 120 years of laboratory glassware

22-Jan-2013 - Germany

His invention revolutionised modern chemistry: at the end of the 19th century, Otto Schott, founder of modern glass technology and what is now SCHOTT AG, invented a laboratory glass made from borosilicate glass, a completely new type of technical glass. It was the first special glass with high resistance to chemicals, heat and temperature changes and was launched on the market in 1893 and registered under the brand name DURAN in 1938. Over the past 120 years, DURAN laboratory glassware has made its mark in the history of technology and is still used as a standard glass in laboratories, industry applica-tions and households around the world today.

120 years DURAN laboratory glassware

In 2013, the DURAN Group is celebrating the anniversary of "its" laboratory glass in German-speaking countries (Germany, Austria and Switzerland) with a campaign in the laboratory glassware sector. The creative idea: by means of a job advertisement, DURAN is searching for a laboratory employee with 120 years of experience. DURAN users are asked to photograph their oldest piece of laboratory glassware and upload it into the online anniversary gallery at www.duran-group.com/120years. The campaign will run from 2 January until 30 April 2013. All participants will be entered into a draw to win one of two Apple iPad3 devices.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Genetic Research: The New Battleground in the Fight Against Heart Disease - University of Ottawa Heart Institute Leads a New Scientific Focus on Preventive Medicine Aimed at Eliminating Heart Disease

Researchers effectively treat tumors with use of nanotubes

Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board

Currently positioned only 5th, China is the fastest growing biotech market in the world

BGU researchers make scientific breakthrough in the fight against neurodegenerative diseases - BGN Technologies secures funding of over $1m. to develop patented treatment

Pivotal phase IIIa trials for Organon's novel oral contraceptive, NOMAC/E2, complete recruitment

Gene Logic Expands GeneExpress Product Line, Launches GeneExpress Women's Health DataSuite - New Product Enables Analysis of Distinctions in Female and Male/ Female Gene Expression

Cangene's VIG (Vaccinia Immune Globulin Intravenous) contract with U.S. government extended for another five years

MediGene successfully completes patient recruitment into EndoTAG(TM)-1 Phase II breast cancer trial

Immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine - IMA950 to enter Phase I development for glioblastoma, the most aggressive form of brain cancer

New findings about stem cells in the brain of patients with epilepsy

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur